New Zealand Markets closed

bioMérieux S.A. (BMXMF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
81.850.00 (0.00%)
At close: 03:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close81.85
Open81.15
BidN/A x N/A
AskN/A x N/A
Day's range81.85 - 81.85
52-week range78.06 - 148.50
Volume15
Avg. volume79
Market cap9.675B
Beta (5Y monthly)-0.06
PE ratio (TTM)19.91
EPS (TTM)4.11
Earnings dateN/A
Forward dividend & yield0.91 (0.85%)
Ex-dividend date06 Jun 2022
1y target estN/A
  • Business Wire

    Baxter and bioMérieux Announce CE Mark for NEPHROCLEAR™ CCL14 Test to Predict Persistent Severe Acute Kidney Injury

    DEERFIELD, Ill. & MARCY L’ETOILE, France, October 21, 2021--Baxter International Inc. (NYSE:BAX), a global leader in acute care, and bioMérieux (EPA:BIM), a global leader in in vitro diagnostics, today announced the CE marking of the NEPHROCLEAR™ CCL14 Test. The NEPHROCLEAR™ CCL14 Test is designed to predict persistent severe acute kidney injury (PS-AKI) and can be used to support timely clinical decision-making and care pathways. The companies intend to commercially launch the NEPHROCLEAR™ CCL1